Not a home run, but first base: GSK un­wraps PhII da­ta on he­pati­tis B treat­ment in pur­suit of ‘func­tion­al cure’

At the an­nu­al Liv­er Meet­ing on Tues­day, GSK un­veiled re­sults from a Phase II tri­al on its he­pati­tis B treat­ment, which it said ear­li­er this year could “lead to a func­tion­al cure” for the liv­er in­fec­tion.

In 457 pa­tients treat­ed with GSK’s bepirovirsen, 26 had un­de­tectable lev­els of he­pati­tis B 24 weeks af­ter treat­ment — mea­sured by the amount of he­pati­tis B sur­face anti­gen and vi­ral DNA. That amounts to about 6% of all pa­tients, ac­cord­ing to the study pub­lished in NE­JM, but re­sults var­ied wide­ly be­tween groups of pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.